Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AZD1386
/
AstraZeneca
Welcome,
Profile
Billing
Logout
18 Diseases
0 Trials
0 Trials
4 News
||
||||||||
Retrospective data, Review, Journal:
Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis.
(Pubmed Central) - Mar 23, 2021
We also conducted a meta-analysis of T data from human trials and found that polymodal TRPV1 antagonists (ABT-102, AZD1386, and V116517) increase T, whereas the mode-selective blocker NEO6860 does not. Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed.
|
|||||||||
AZD1386
/
AstraZeneca
Enrollment change:
Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)
(clinicaltrials.gov) - Oct 9, 2012
P2a
, N=14, Completed,
Sponsor: AstraZeneca
Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed. N=30 --> 14
||||||||||
AZD1386
/
AstraZeneca
Enrollment change:
Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee
(clinicaltrials.gov) - May 27, 2012
P2
, N=241, Terminated,
Sponsor: AstraZeneca
N=30 --> 14 N=520 --> 241